Form D · Pharmaceuticals
SALIX PHARMACEUTICALS LTD
Raleigh, NC · CIK 0001009356
Offering snapshot reported Jan 10, 2014 · SEC filing
- Reported sold
- $750M Offering amount: $750M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 27, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 10, 2014 | Initial | $750,000,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-209813
Refer to the Company's Current Report on Form 8-K filed with the SEC on 12/27/2013.
Source: Form D, filed Jan 10, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John F. Chappell | Director |
| Thomas W. D'alonzo | Director |
| Adam C. Derbyshire | Executive |
| William P. Forbes | Executive |
| William P. Keane | Director |
| Carolyn J. Logan | Director, Executive |
| Rick D. Scruggs | Executive |
| Mark A. Sirgo | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
8510 Colonnade Center Drive
Raleigh, NC, 27615
Raleigh, NC, 27615